ATE407698T1

Compositions and methods for the therapy of inflammatory bowel disease

Abstract

Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).

Term

Term ended

Projected expiry passed 23 April 2024, 2.4 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

39 members in 21 offices

This recordMember, by publication datePriority claim11 more offices are in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
46515503United States of AmericaP

Members39

Family members, oldest first
DocumentOfficeKind
AU2004232362A1AustraliaA1
CA2522957A1CanadaA1
CA2823468A1CanadaA1
WO2004093908A2World Intellectual Property Organization (WIPO)A2
WO2004093908A3World Intellectual Property Organization (WIPO)A3
US2005152901A1United States of AmericaA1
MXPA05011409AMexicoA
KR20060015531ARepublic of KoreaA
EP1631312A2European Patent Office (EPO)A2
CN1777444AChinaA
BRPI0410495ABrazilA
ZA200508390BSouth AfricaB
JP2006524703AJapanA
AU2004232362B2AustraliaB2
AU2007203559A1AustraliaA1
KR100817351B1Republic of KoreaB1
AU2004232362C1AustraliaC1
CN100409897CChinaC
EP1631312B1European Patent Office (EPO)B1
AT407698TAustriaT
ATE407698T1This recordAustriaT1
DE602004016499D1GermanyD1
CN101318019AChinaA
PT1631312EPortugalE
DK1631312T3DenmarkT3
PL1631312T3PolandT3
SI1631312T1SloveniaT1
ES2313039T3SpainT3
NZ542866ANew ZealandA
AU2007203559B2AustraliaB2
IL171356AIsraelA
AU2010249151A1AustraliaA1
JP4628357B2JapanB2
US7939076B2United States of AmericaB2
US2011165158A1United States of AmericaA1
SG173919A1SingaporeA1
CN101318019BChinaB
CA2522957CCanadaC
US8828393B2United States of AmericaB2